https://www.selleckchem.com/Bcl-2.html
Niraparib maintenance after frontline chemotherapy for advanced ovarian cancer extends progression free survival. The objective of this study was to determine the cost effectiveness of niraparib maintenance therapy in patients with newly diagnosed ovarian cancer. Decision analysis models compared the cost of observation versus niraparib maintenance following chemotherapy for five groups all newly diagnosed ovarian cancer patients (overall), those with homologous recombination deficiency, those harboring mutations ( ), homologous recombination defi
Like
Comment
Share
